Pulse Biosciences (NASDAQ:PLSE) Stock Price Down 11.7% – Time to Sell?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares traded down 11.7% on Tuesday . The company traded as low as $19.81 and last traded at $20.2530. 47,845 shares changed hands during trading, a decline of 85% from the average session volume of 326,763 shares. The stock had previously closed at $22.94.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, January 22nd. Oppenheimer restated an “outperform” rating and issued a $30.00 price objective on shares of Pulse Biosciences in a report on Friday, February 20th. Mizuho set a $30.00 price objective on shares of Pulse Biosciences in a report on Friday, February 6th. Finally, Wall Street Zen upgraded shares of Pulse Biosciences from a “sell” rating to a “hold” rating in a report on Saturday, February 21st. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $30.00.

Pulse Biosciences Price Performance

The business’s 50 day moving average is $20.43 and its 200-day moving average is $17.18. The company has a market cap of $1.30 billion, a PE ratio of -17.65 and a beta of 1.70.

Pulse Biosciences (NASDAQ:PLSE) last issued its quarterly earnings results on Thursday, February 19th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.06.

Insider Transactions at Pulse Biosciences

In other news, insider Kevin Patrick Danahy sold 20,000 shares of the business’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $23.53, for a total transaction of $470,600.00. Following the completion of the sale, the insider owned 43,298 shares in the company, valued at approximately $1,018,801.94. The trade was a 31.60% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders have sold a total of 85,000 shares of company stock valued at $1,994,400 in the last ninety days. 74.60% of the stock is owned by insiders.

Institutional Trading of Pulse Biosciences

Institutional investors have recently modified their holdings of the stock. BNP Paribas Financial Markets lifted its position in shares of Pulse Biosciences by 63.6% during the 2nd quarter. BNP Paribas Financial Markets now owns 1,749 shares of the company’s stock worth $26,000 after buying an additional 680 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Pulse Biosciences by 275.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 2,940 shares of the company’s stock worth $44,000 after buying an additional 2,156 shares during the last quarter. Russell Investments Group Ltd. lifted its position in shares of Pulse Biosciences by 44.0% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,487 shares of the company’s stock worth $79,000 after buying an additional 1,372 shares during the last quarter. KLP Kapitalforvaltning AS lifted its position in shares of Pulse Biosciences by 136.0% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 5,900 shares of the company’s stock worth $104,000 after buying an additional 3,400 shares during the last quarter. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Pulse Biosciences during the 2nd quarter worth approximately $158,000. Hedge funds and other institutional investors own 76.95% of the company’s stock.

About Pulse Biosciences

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.